uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
GLP-1 playing the role of a gut regulatory compound
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences. (Gastroenterologi/Hellström)
2011 (English)In: Acta Physiologica, ISSN 1748-1708, E-ISSN 1748-1716, Vol. 201, no 1, 151-156 p.Article, review/survey (Refereed) Published
Abstract [en]

Gastric emptying is the first step in the metabolic endocrine cascade that takes place after food intake. The incretin hormones originating in the gut, particularly GLP-1, exert multiple antihyperglycaemic actions such as enhancement of glucose-dependent insulin secretion, suppression of glucagon secretion, slowing of gastric emptying with an ensuing decrease in food intake and weight loss. From extensive studies in experimental animals and humans we have found that GLP-1 also exerts a motility-inhibiting and antispasmodic effect in the gut that was verified in healthy volunteers and patients with irritable bowel syndrome (IBS). In order to further investigate the effect of GLP-1 in humans, we used the dipeptidyl peptidase-IV resistant GLP-1 analogue ROSE-010, thereby extending its biological activity. A randomized, double-blinded, prospective clinical trial was carried out in order to investigate the effect of two doses of ROSE-010 in 166 patients suffering from pain attacks of IBS. We found that injections of ROSE-010 were twice as effective as placebo in terms of total pain relief response in those affected by pain attacks due to IBS. Our results show that basal physiological research studies can be translated into clinical use. The current pharmaceutical incentive with incretin mimetics, such as GLP-1 analogues and exenatide, is an interesting development that apart from its obvious use in diabetes type 2, may also be useful in terms of gut motility-regulating effects with effects on appetite, food intake and motility disorders that may provide an opportunity to bring about new improvements in medical care.

Place, publisher, year, edition, pages
2011. Vol. 201, no 1, 151-156 p.
Keyword [en]
gastrointestinal peptide hormones, glucagon-like peptides, glucose disposal, irritable bowel syndrome, metabolic control
National Category
Gastroenterology and Hepatology
Research subject
Medical Science
URN: urn:nbn:se:uu:diva-142837DOI: 10.1111/j.1748-1716.2010.02150.xISI: 000285153100016PubMedID: 20518750OAI: oai:DiVA.org:uu-142837DiVA: diva2:388303
Available from: 2011-01-17 Created: 2011-01-17 Last updated: 2012-03-13Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Hellström, Per M.
By organisation
Department of Medical Sciences
In the same journal
Acta Physiologica
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 143 hits
ReferencesLink to record
Permanent link

Direct link